Coreline Soft enters Australia as 1st cancer screening begins in 20 years

Sydney’s Nepean Diagnostics, a private imaging center within Nepean Private Hospital, has become the beachhead for Coreline Soft’s AVIEW LCS Plus, giving Australian radiologists an AI tool that flags the “big three” in lung cancer screening: lung nodules, emphysema, and coronary-artery calcium in a single low-dose CT pass. 

Coreline announced the rollout Wednesday, following the launch of Australia’s National Lung Cancer Screening Program (NLCSP) on Tuesday for high-risk adults aged 50 to 70.

The initiative marks the country’s first new nationwide screening program since bowel cancer testing began in 2006.

Coreline has spent the past five years building its track record across Europe’s lung cancer screening pilots, including Germany’s HANSE study and Italy’s RISP registry. 

But launching AVIEW LCS Plus just ahead of Australia’s national rollout, CEO Kim Jin-kook said, is “more than just about the technology” and represents a “strategic step toward shaping the country’s lung cancer screening infrastructure.”

The company is leaning on local distributor Paragon Care, a 100-brand supplier with roughly 3 trillion won ($2.2 billion) in annual sales, to seed additional sites following a joint roadshow at this year’s Australian Lung Cancer Conference (ALCC 2025).

With the NLCSP now in effect, inquiries from imaging centers and radiologists about AI-based tools have surged, according to Coreline. The agreement with Nepean, the company says, was a strategic move to secure early validation data and build trust with Australian clinicians.

AVIEW LCS Plus automatically detects and segments lung nodules, calculates volumes and doubling times, populates PanCan risk scores, and generates structured reports aligned with national guidelines.

According to Coreline’s internal time-and-motion study, the software can reduce average reading time per screening batch by 60 percent -- from 585 minutes to 235 minutes. The company reports a 79.5 percent return on investment, factoring in radiologist labor and reductions in follow-up scans.

The company says the product is designed to streamline interpretation under Australia’s NLCSP protocols, which assign each scan a risk category that determines follow-up timing.

AVIEW LCS Plus integrates those risk tiers directly into its reporting template to support compliance with the program’s structured workflow.